Volunteer's suicide does not exempt drug in clinical trial from liability

Volunteer's suicide does not exempt drug in clinical trial from liability

Published on November 10, 2020

This episode, if it was indeed a suicide, does not exempt the vaccine.

In a multicenter, randomized, double-blind, phase III clinical trial of comparative efficacy between a 48-week hepatitis C treatment with alpha-interferon associated with ribavirin VS a 24-week treatment with pegylated interferon (pegui-interferon) also associated with ribavirin, conducted between 1999 and 2003, the rate of suicide attempts, catatonic and paranoid-delusional outbreaks was statistically relevant. Pegui-interferon, as well as alpha-interferon, are produced by molecular engineering or molecular pharmacology, the same used for the production of these vaccines for respiratory viruses.

SARS-CoV-2 vaccines are produced from specific viral fragments, modified through molecular pharmacology processes, and may elicit unpredictable reactions on the psyche, which differs from vaccines derived from concentrates or cultures of attenuated viruses. The latter typically induce only physiological, allergic, or even anaphylactic effects, in addition to, albeit rarely, the development of the disease they are intended to prevent in a small subset of vaccine recipients. Read more

Imprimir
[Back]